Posted inNasdaq Nordic
Sprint Bioscience sells the TREX1 program to Gilead for up to USD 400 million
STOCKHOLM: Sprint Bioscience AB (publ) today announces the sale of its TREX1 cancer program to Gilead Sciences, Inc. The agreement includes an upfront payment of USD 14 million, as well…